Zhitong Finance App News, Shuanglu Pharmaceutical (002038.SZ) issued an announcement. The company recently received the “Drug Registration Certificate” for bromhexine hydrochloride oral solution (trade name: Beliqing®) approved and issued by the China Drug Administration (hereinafter referred to as the “State Drug Administration”).

Bromhexine hydrochloride oral solution is mainly suitable for symptomatic treatment of respiratory diseases associated with impaired mucus secretion or mucus removal in adults, adolescents and children aged 6 and above, including acute bronchitis, tracheobronchitis, chronic bronchitis, chronic obstructive bronchopulmonary disease, bronchiectasis, acute sinusitis, and chronic rhinosinusitis. This product was first developed by Sanofi in Belgium. The trade name is Bisolvon®. Currently, many domestic companies have listed the product. The variety has entered the national medical insurance. The 40ml:80mg specification entered the “National Essential Drugs List (2026 edition)” in July 2026 and was officially implemented in September 2026. This product will be produced by a new production workshop at the company's Daxing base.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.